JP2023550446A5 - - Google Patents

Info

Publication number
JP2023550446A5
JP2023550446A5 JP2023530329A JP2023530329A JP2023550446A5 JP 2023550446 A5 JP2023550446 A5 JP 2023550446A5 JP 2023530329 A JP2023530329 A JP 2023530329A JP 2023530329 A JP2023530329 A JP 2023530329A JP 2023550446 A5 JP2023550446 A5 JP 2023550446A5
Authority
JP
Japan
Prior art keywords
sequence
antigen
antibody
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023530329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550446A (ja
JP7886328B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/082383 external-priority patent/WO2022106665A1/en
Publication of JP2023550446A publication Critical patent/JP2023550446A/ja
Publication of JP2023550446A5 publication Critical patent/JP2023550446A5/ja
Application granted granted Critical
Publication of JP7886328B2 publication Critical patent/JP7886328B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023530329A 2020-11-20 2021-11-19 抗cd25抗体 Active JP7886328B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20306424.1 2020-11-20
EP20306424 2020-11-20
PCT/EP2021/082383 WO2022106665A1 (en) 2020-11-20 2021-11-19 Anti-cd25 antibodies

Publications (3)

Publication Number Publication Date
JP2023550446A JP2023550446A (ja) 2023-12-01
JP2023550446A5 true JP2023550446A5 (cg-RX-API-DMAC7.html) 2024-11-25
JP7886328B2 JP7886328B2 (ja) 2026-07-07

Family

ID=73698744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023530329A Active JP7886328B2 (ja) 2020-11-20 2021-11-19 抗cd25抗体

Country Status (9)

Country Link
US (1) US20240002522A1 (cg-RX-API-DMAC7.html)
EP (1) EP4247497A1 (cg-RX-API-DMAC7.html)
JP (1) JP7886328B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230118108A (cg-RX-API-DMAC7.html)
CN (1) CN116917318A (cg-RX-API-DMAC7.html)
AR (1) AR124123A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021380966A1 (cg-RX-API-DMAC7.html)
CA (1) CA3199006A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022106665A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222886A1 (en) 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US61816A (en) 1867-02-05 bunbab and a
US96973A (en) 1869-11-16 saxton
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
WO2013165972A2 (en) * 2012-04-30 2013-11-07 Cell Signaling Technology, Inc. Anti-hepatitis b virus antibodies and use thereof
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
WO2019008386A1 (en) * 2017-07-06 2019-01-10 Tusk Therapeutics Ltd COMPOUNDS AND METHODS FOR DEPLOYING SPECIFIC CELLS FROM A TUMOR
CN112020516B (zh) * 2018-03-13 2025-01-03 塔斯克疗法有限公司 用于肿瘤特异性细胞清除的抗-cd25
BR112021008486A2 (pt) * 2018-11-01 2021-10-26 Shandong New Time Pharmaceutical Co., Ltd Anticorpo biespecífico e seu uso
CN114630838A (zh) * 2019-05-20 2022-06-14 法国国家健康和医学研究院 新的抗cd25抗体

Similar Documents

Publication Publication Date Title
JP7143452B2 (ja) CD47とSIRPaの相互作用を遮断できる抗体及びその応用
US11203633B2 (en) Polynucleotides encoding antibodies or antigen binding fragments thereof that bind pseudomonas perv
JP2022031635A5 (cg-RX-API-DMAC7.html)
RU2019141289A (ru) АНТИ-SIRPα АНТИТЕЛА
KR20220024729A (ko) B-세포 성숙 항원을 표적으로 하는 다중특이성 항체에 대한 투여 요법 및 병용 요법
RU2019140602A (ru) АНТИ-GARP-TGF-β-АНТИТЕЛА
JP2021501162A5 (cg-RX-API-DMAC7.html)
JP2019527194A5 (cg-RX-API-DMAC7.html)
JP2020513791A5 (cg-RX-API-DMAC7.html)
JP2020511947A5 (cg-RX-API-DMAC7.html)
JP2018505177A5 (cg-RX-API-DMAC7.html)
JP2017535257A5 (cg-RX-API-DMAC7.html)
JP2016505546A5 (cg-RX-API-DMAC7.html)
HRP20190605T1 (hr) Protutijela anti-fxi i postupci njihove uporabe
JP2012525829A5 (cg-RX-API-DMAC7.html)
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
JP2022538733A5 (cg-RX-API-DMAC7.html)
JP2024532489A5 (cg-RX-API-DMAC7.html)
JP2021525806A5 (cg-RX-API-DMAC7.html)
JP2024541680A5 (cg-RX-API-DMAC7.html)
JP2024016024A5 (cg-RX-API-DMAC7.html)
JP2018093875A5 (cg-RX-API-DMAC7.html)
JP2021511387A5 (cg-RX-API-DMAC7.html)
JP2023543493A5 (cg-RX-API-DMAC7.html)
JP2021518132A5 (cg-RX-API-DMAC7.html)